JournalArta
Sunday, November 22, 2026 · JakartaS&P 6,910.39 ▼3.70%USD/IDR 18,158 ▼0.42%
JournalArta
Global Edition
beyond headlines
Advertisement

Target and Genmab Show Strength as S&P 500 Falls

Target and Danish biotech Genmab are among five stocks showing relative strength against the S&P 500 after a record weekly point loss. Target raised its earnings outlook, while Genmab reported positive cancer trial results. Cheesecake Factory, Netskope and Welltower also made the list.

By Alistair Sterling
WIB2 min read
Target and Genmab Show Strength as S&P 500 Falls
Target and Genmab Show Strength as S&P 500 Falls

Target and biotech company Genmab are among five stocks showing relative strength against the S&P 500 after the index’s worst weekly point loss on record. The group spans retail, restaurants, cybersecurity, cancer drugs and senior housing.

Target shares rose 2.7% for the week to 165.83 after the retailer raised its full-year earnings forecast. Genmab shares fell 1.5% to 50.60, following a 60% surge in October.

Target raises its earnings forecast

Target reported 49% growth in third-quarter earnings per share on 7% revenue growth. It raised its full-year earnings-per-share forecast to $10.65–$11.40 from $9.90–$10.90.

Advertisement

Truist analysts said nearly 60% of Target’s 5.6% comparable-store sales growth came from its Fun 101 category. The category includes revamped Fan Shops, which have helped drive trading card sales.

Truist cautioned that demand for collectibles can be fickle. The analysts said Target’s turnaround under new CEO Michael Fiddelke needs to broaden into apparel and home goods.

Cheesecake Factory shares ended the week down 1.1% at 107.95, despite a 7.2% jump during the week. The restaurant chain’s stock has moved largely sideways since October 27, while the S&P 500 has fallen 10%.

Comparable-store sales at its core Cheesecake Factory restaurants rose 15.2%. Traffic increased 9.5%, while the average ticket rose 5.7%, reflecting ordering choices and a 2.4% price increase.

Advertisement

William Blair analyst Sharon Zackfia highlighted menu changes, loyalty programs and “encouraging traction with younger guests.” She also pointed to increased alcohol consumption and sales of lower-priced Bites menu items.

Genmab reports cancer trial progress

Genmab’s October gains followed three positive developments in cancer treatment studies. Its Epkinly drug beat standard treatment in patients with a form of lymphoma, while Rina-S succeeded in a final-phase ovarian cancer study.

Genmab said a regimen using its drug petosemtamab cut the risk of death by 50% for patients with head-and-neck cancer. The stock reached a record high of 59.97 on October 28.

Advertisement

Netskope attracted two analyst price-target increases amid attention to artificial intelligence security threats. Rosenblatt raised its target to 28 from 19, while TD Cowen raised its target to 25 from 19.

Netskope shares rose 12.7% in one session during the week, then pulled back 3.5% in the final session. The cybersecurity company reports third-quarter results after the market closes on December 2.

Welltower reported 25% growth in normalized funds from operations, a measure of real estate operating performance, on 38% revenue growth in the third quarter. Rent increases accounted for 5.3% of the growth.

On its October 27 earnings call, Welltower said it had entered $21 billion in investments for the year, closing $13.3 billion through the third quarter.

Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Magnitude 4.2 Earthquake Wakes Los Angeles Before DawnMagnitude 4.2 Earthquake Wakes Los Angeles Before Dawn
  2. 2Dow Jones Futures Await Reopening After Tech Stocks SlideDow Jones Futures Await Reopening After Tech Stocks Slide
  3. 3Micron Says Memory Has Changed as Shares Fall 13.89%Micron Says Memory Has Changed as Shares Fall 13.89%
  4. 4GTA 6 Draws Review Bombing on MetacriticGTA 6 Draws Review Bombing on Metacritic
  5. 5ORCL Stock Week Ahead: Levels and Scenarios for November 23–27ORCL Stock Week Ahead: Levels and Scenarios for November 23–27
Advertisement
Don't Miss

Latest News

All stories →
  1. Steve Coogan and Rob Brydon Take The Trip to ScandinaviaLifestyle · EntertainmentSteve Coogan and Rob Brydon Take The Trip to ScandinaviaNov 22
  2. Netflix Falls Below $60 as Revenue Growth SlowsMarkets · StocksNetflix Falls Below $60 as Revenue Growth SlowsNov 22
  3. Bhaskar Bhat Questions Venu Srinivasan and Vijay SinghBusiness · CompaniesBhaskar Bhat Questions Venu Srinivasan and Vijay SinghNov 22
  4. Broadcom Shares Fall as AI Chip Competition Raises ConcernsMarkets · StocksBroadcom Shares Fall as AI Chip Competition Raises ConcernsNov 22
  5. Advertisement
  6. Microsoft Stock Gave Back 9% After Record CloseMarkets · StocksMicrosoft Stock Gave Back 9% After Record CloseNov 22
  7. Micron Stock Hits Lowest Close Since Early MayMarkets · StocksMicron Stock Hits Lowest Close Since Early MayNov 22
  8. Nifty 50 Reaches Nine-Month High as Foreign Buying Lifts StocksMarkets · StocksNifty 50 Reaches Nine-Month High as Foreign Buying Lifts StocksNov 22
  9. Prince Harry Could Lose Titles Under William’s Reported PlanLifestyle · EntertainmentPrince Harry Could Lose Titles Under William’s Reported PlanNov 22